ERBB2 and breast carcinoma: Correlative biomarker analysis of the BOLERO2 trial assessing the efficacy of everolimus in combination with exemestane in HR+/HER2- refractory advanced breast cancers showed that PFS was independent of underlying genetic alteration of PIK3CA [13, 39].